|
|
Supplemental
ascorbate in the supportive treatment of cancer: reevaluation of prolongation of
survival times in terminal human cancer
Cameron E, Pauling L
A study has been made of the survival times of 100 terminal
cancer patients who were given supplemental ascorbate, usually 10 g/day, as part
of their routine management and 1000 matched controls, similar patients who had
received the same treatment except for the ascorbate.
The two sets of patients were in part the same as those used in our earlier
study [Cameron, E. & Pauling, L. (1976) Proc. Natl. Acad. Sci. USA
73, 3685-3689].
Tests confirm that the ascorbate-treated patients and the matched controls are
representative subpopulations of the same population of “untreatable”
patients.
Survival times were measured not only from the date of “untreatability” but
also from the precisely known date of first hospital attendance for the cancer
that eventually reached the terminal stage.
The ascorbate-treated patients were found to have a mean survival time about 300
days greater than that of the controls.
Survival times greater than 1 yr after the date of untreatability were observed
for 22% of the ascorbate-treated patients and for 0.4% of the controls.
The mean survival time of these 22 ascorbate-treated patients is 2.4 yr after
reaching the apparently terminal stage; 8 of the ascorbate-treated patients are
still alive, with a mean survival time after untreatability of 3.5 yr.
PMID: 279931 [PubMed - indexed for MEDLINE]
|
